Leerink Partnrs Has Negative Outlook of VKTX FY2025 Earnings
Analysts at Leerink Partnrs decreased their FY2025 earnings estimates for Viking Therapeutics in a research note issued to ...
Tourmaline Bio FY2024 EPS Forecast Raised by Leerink Partnrs
Investment analysts at Leerink Partnrs increased their FY2024 earnings per share (EPS) estimates for Tourmaline Bio in a ...
T-knife Therapeutics to Participate in Two Investor Conferences in March
SAN FRANCISCO and BERLIN, Feb. 12, 2025 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a biopharmaceutical company developing T cell receptor (TCR) engineered T cell therapies (TCR-T) to fight cancer ...
Investment Banker Cleared to Seek Multi-Million Bonuses Against Former Boston Employer
U.S. District Judge Angel Kelley for the District of Massachusetts allowed state law claims to move forward in a suit brought by an investment banker who claims Leerink Partners failed to pay minimum ...
Analysts Are Bullish on These Healthcare Stocks: Arvinas Holding Company (ARVN), Arcus Biosciences (RCUS)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Arvinas Holding Company (ARVN – Research ...
Investing7h
CVS Health shares surge as quarterly earnings top estimates amid turnaround push
CVS's medical benefit ratio -- a closely-monitored metric tracking the premiums spent on medical care for insurance holders -- was 94.8%, down from a record high of 95.2% in the prior quarter. The ...
Regeneron Announces Investor Conference Presentations
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: TD Cowen 45th Annual Health Care Conference at 11:50 a.m. ET on Tuesday, March 4, 2025Leerink Partners ...
Investing1h
Stifel handhaaft koopadvies voor Alto Neuroscience met koersdoel van $10
Stifel-analisten hebben woensdag hun koopadvies en koersdoel van $10,00 voor Alto Neuroscience (NYSE: ANRO) gehandhaafd, wat wijst op positieve vooruitzichten voor het aandeel. Het aandeel, dat moment ...
VINC stock touches 52-week low at $1.3 amid market challenges
In a turbulent market environment, Vincerx Pharma, Inc. (VINC) stock has reached its 52-week low, trading at $1.3. According to InvestingPro analysis, the company maintains a healthy current ratio of ...
Investing4h
AbbVie en Xilio bundelen krachten voor tumor-geactiveerde therapieën
Dr. Theodora S. Ross van AbbVie benadrukte het potentieel van de samenwerking om hun R&D-inspanningen te versterken en kankerbehandelingen van de volgende generatie te ontwikkelen. Dr. Uli Bialucha ...